Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 8/20 | 0.48 |
| ▸ | CCND1 | P24385 | 7/20 | 0.48 |
| ▸ | CCND3 | P30281 | 7/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 6/20 | 0.48 |
| ▸ | CDK2 | P24941 | 5/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.48 |
| ▸ | CDK9 | P50750 | 4/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.48 |
| ▸ | CDK7 | P50613 | 2/20 | 0.48 |
| ▸ | CCNH | P51946 | 2/20 | 0.48 |
| ▸ | CCND2 | P30279 | 2/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 9/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13812507 | 0.86 | CTSC (0.45) | CDK4CCND1CCND3CDK6CDK2 | |
| SCHEMBL4073403 | 0.86 | CDK4 (0.54) | CDK4CCND1CCND3CDK6CDK2 | |
| SCHEMBL4067659 | 0.86 | CDK2 (0.39) | CDK4CCND1CCND3CDK6CDK2 | |
| Ammonia Solution, Strong SCHEMBL4445953 | 0.84 | CDK4 (0.48) | CDK4CCND1CCND3CDK6CDK2 | |
| SCHEMBL5520583 | 0.76 | SYK (0.65) | CDK4CCND1CCND3CDK2CCNA2 | |
| SCHEMBL14001913 | 0.75 | SYK (0.64) | CDK4CCND1CCND3CDK2CCNA2 | |
| SCHEMBL5511671 | 0.75 | SYK (0.54) | SYK | |
| SCHEMBL5513153 | 0.75 | SYK (0.65) | CDK4CCND1CCND3CDK2CCNA2 | |
| SCHEMBL4065714 | 0.74 | CDK4 (0.53) | CDK4CCND1CCND3CDK6CDK2 | |
| SCHEMBL12639219 | 0.74 | SYK (0.64) | CDK4CCND1CCND3CDK2CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590341-B1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2009-06-17 | — | — | EP | claimed |
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | PFIZER INC | 2004-11-25 | — | — | US | claimed |
| EP-1590341-B1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090030005-A1 | Combinations for the treatment of cancer | AMGEN INC. (US) | 2009-01-29 | — | — | US | disclosed |
| EP-1740184-A1 | COMBINATIONS OF SIGNAL TRANSDUCTION INHIBITORS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1590341-A1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005094830-A1 | COMBINATIONS OF SIGNAL TRANSDUCTION INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| WO-2004065378-A1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | CDK4, CCNA1, CCNI | CDK4 1/4885CCND1 11/4885CCND3 32/4885 |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | CDK4, CDK3, CDK2 | CDK4 1/4885CCND1 66/4885CCND3 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.